Detalhe da pesquisa
1.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 2024 Jun 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38832972
2.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38084760
3.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 2024 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38828933
4.
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lancet Oncol
; 2024 May 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38821074
5.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38697166
6.
Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.
Br J Haematol
; 204(4): 1439-1449, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37807708
7.
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Haematologica
; 109(3): 867-876, 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37646657
8.
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Haematologica
; 109(3): 895-905, 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37646660
9.
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
Ann Hematol
; 103(3): 981-992, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38092996
10.
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
Am J Hematol
; 2024 Jun 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38856176
11.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37717583
12.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37269857
13.
Length-Dependent Translation Efficiency of ER-Destined Proteins.
Curr Issues Mol Biol
; 45(8): 6717-6727, 2023 Aug 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37623244
14.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
Inglês
| MEDLINE | ID: mdl-32786187
15.
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
J Transl Med
; 21(1): 197, 2023 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36922828
16.
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Ann Hematol
; 102(6): 1501-1511, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37088816
17.
Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
Int J Mol Sci
; 24(6)2023 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36982699
18.
Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres.
Br J Haematol
; 197(3): 302-305, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35076937
19.
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
Br J Haematol
; 198(6): 988-993, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35608261
20.
Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Br J Haematol
; 196(4): 954-962, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34726261